Hubei Jumpcan Pharmaceutical Co Ltd Asset Resilience Ratio
Hubei Jumpcan Pharmaceutical Co Ltd asset resilience ratio. Hubei Jumpcan Pharmaceutical Co Ltd (600566) has an Asset Resilience Ratio of 47.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Hubei Jumpcan Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hubei Jumpcan Pharmaceutical Co Ltd (2002–2025)
Asset resilience ratio of Hubei Jumpcan Pharmaceutical Co Ltd from 2002 to 2025. This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 600566 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Hubei Jumpcan Pharmaceutical Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥8.02 Billion | 47.16% |
| Total Liquid Assets | CN¥8.02 Billion | 47.16% |
Asset Resilience Insights
- Very High Liquidity: Hubei Jumpcan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 47.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Jumpcan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hubei Jumpcan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Hubei Jumpcan Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2002–2025)
Hubei Jumpcan Pharmaceutical Co Ltd asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.40% | CN¥6.27 Billion ≈ $916.85 Million |
CN¥17.70 Billion ≈ $2.59 Billion |
+7.44pp |
| 2024-12-31 | 27.96% | CN¥5.16 Billion ≈ $755.21 Million |
CN¥18.46 Billion ≈ $2.70 Billion |
+10.44pp |
| 2023-12-31 | 17.52% | CN¥3.18 Billion ≈ $465.08 Million |
CN¥18.14 Billion ≈ $2.65 Billion |
-2.81pp |
| 2022-12-31 | 20.32% | CN¥3.04 Billion ≈ $445.51 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+6.51pp |
| 2021-12-31 | 13.81% | CN¥1.68 Billion ≈ $245.11 Million |
CN¥12.13 Billion ≈ $1.78 Billion |
+1.84pp |
| 2020-12-31 | 11.96% | CN¥1.26 Billion ≈ $184.08 Million |
CN¥10.52 Billion ≈ $1.54 Billion |
+9.77pp |
| 2019-12-31 | 2.19% | CN¥190.00 Million ≈ $27.80 Million |
CN¥8.66 Billion ≈ $1.27 Billion |
-1.50pp |
| 2018-12-31 | 3.69% | CN¥288.00 Million ≈ $42.14 Million |
CN¥7.80 Billion ≈ $1.14 Billion |
-6.39pp |
| 2017-12-31 | 10.09% | CN¥672.00 Million ≈ $98.33 Million |
CN¥6.66 Billion ≈ $974.94 Million |
+5.88pp |
| 2016-12-31 | 4.21% | CN¥210.00 Million ≈ $30.73 Million |
CN¥4.99 Billion ≈ $729.84 Million |
+0.58pp |
| 2015-12-31 | 3.63% | CN¥130.00 Million ≈ $19.02 Million |
CN¥3.59 Billion ≈ $524.66 Million |
-4.71pp |
| 2014-12-31 | 8.34% | CN¥280.00 Million ≈ $40.97 Million |
CN¥3.36 Billion ≈ $491.34 Million |
+8.29pp |
| 2006-12-31 | 0.05% | CN¥400.00K ≈ $58.53K |
CN¥786.51 Million ≈ $115.09 Million |
-5.83pp |
| 2003-12-31 | 5.88% | CN¥38.22 Million ≈ $5.59 Million |
CN¥650.39 Million ≈ $95.17 Million |
-1.38pp |
| 2002-12-31 | 7.26% | CN¥44.08 Million ≈ $6.45 Million |
CN¥607.22 Million ≈ $88.85 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines in China. The company offers drugs in the fields of pediatrics, respiratory system, digestive system, and gynecology. It is also involved in daily chemical product sales; and wholesale and retail pharmaceuticals. The company is headquartered in Taixing, China.